Milestone Pharmaceuticals (NASDAQ:MIST) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 187.36% from the company's current price.

A number of other research firms have also recently issued reports on MIST. TD Securities cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Cowen cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen cut Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.00.

Milestone Pharmaceuticals Stock Performance

MIST traded up $0.09 during trading hours on Thursday, hitting $1.74. 789,111 shares of the stock were exchanged, compared to its average volume of 916,470. The stock has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.69. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The stock has a market cap of $93.03 million, a price-to-earnings ratio of -2.15 and a beta of 0.92. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MIST. Propel Bio Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter valued at $1,161,000. Toronto Dominion Bank acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $1,770,000. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $729,000. Walleye Capital LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter valued at $74,000. Finally, Virtu Financial LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $170,000. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.